Research.Patient.info
Relapsed/Refractory Peripheral T-cell Lymphoma research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE1
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This study looked at a new drug, tolinapant, combined with Decitabine and Cedazuridine, for people with a difficult-to-treat type of blood cancer called peripheral T-cell lymphoma. Researchers wanted to understand if the drug combination was safe and how well it worked. The study was stopped early because a safe dose couldn't be found.
United States · Australia · France - active not recruitingPHASE2
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
This study looks at a new medicine called Valemetostat Tosylate for people with certain types of T-cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective the medicine is.
United States · Australia · Canada